ATM, CTLA4, MNDA, and HEM1 in high versus low CD38-expressing B-cell chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages 5295-5304

  Joshi, Avadhut D ^a   Hegde, Ganapati V ^a   Dickinson, John D ^a   Mittal, Amit K ^a   Lynch, James C ^a   Eudy, James D ^a   Armitage, James O ^a   Bierman, Philip J ^a   Bociek, R Gregory ^a   Devetten, Marcel P ^a   Vose, Julie M ^a   Joshi, Shantaram S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CD38 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROTEIN; PROTEIN HEM1; PROTEIN MNDA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATM GENE; CANCER GENETICS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CTLA4 GENE; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HEM1 GENE; HUMAN; HUMAN CELL; MALE; MNDA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL CYCLE PROTEINS; CELL PROLIFERATION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 34848829606     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0283     Document Type: Article

References (52)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001. Blood 2006;107:265-76.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
7. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
8. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
9. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A 1980;77:1588-92.
10. Campana D, Suzuki T, Todisco E, Kitanaka A. CD38 in hematopoiesis. Chem Immunol 2000;75:169-88.
11. Malavasi F, Funaro A, Alessio M, et al. CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res 1992;22:73-80.
12. Lund FE, Yu N, Kim KM, Reth M, Howard MC. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J Immunol 1996;157:1455-67.
13. Yasue T, Nishizumi H, Aizawa S, et al. A critical role of lyn and fyn for B cell responses to CD38 ligation and interleukin 5. Proc Natl Acad Sci U S A 1997;94:10307-12.
14. Matrai Z. CD38 as a prognostic marker in CLL. Hematology 2005;10:39-46.
15. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002;16:30-5.
16. Durig J, Nuckel H, Huttmann A, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 2003;101:2748-55.
17. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
18. Del Giudice I, Morilla A, Osuji N, et al. Zetachain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005;104:2124-32.
19. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-55.
20. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for CLL growth and survival. Blood 2005;105:3042-50.
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
22. Hromas R, Collins S, Raskind W, Deaven L, Kaushansky K. Hem-1, a potential membrane protein, with expression restricted to blood cells. Biochim Biophys Acta 1991;1090:241-4.
23. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999;162:5813-20.
24. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002;32:366-73.
25. Geng Y, Choubey D. Differential induction of the 200-family proteins in Daudi Burkitt's lymphoma cells by interferon-α. J Biol Regul Homeost Agents 2000;14:263-8.
26. Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res Treat 2004;83:15-23.
27. Dickinson JD, Smith LM, Sanger WG, et al. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 2005;128:460-71.
28. Jaimes MC, Rojas OL, Kunkel EJ, et al. Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 2004;78:10967-76.
29. Dickinson JD, Joshi A, Iqbal J, Sanger W, Bierman PJ, Joshi SS. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. Int J Mol Med 2006;17:769-78.
30. Dickinson JD, Gilmore J, Iqbal J, et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006;47:231-44.
31. Wang P, Pavletic ZS, Joshi SS. Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation. Leuk Lymphoma 2002;43:1827-35.
32. Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in CLL patients. Leukemia 2005;19:301-4.
33. Miranda RN, Briggs RC, Shults K, Kinney MC, Jensen RA, Cousar JB. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol 1999;30:1040-9.
34. Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001;54:512-6.
35. Shiloh Y. ATM: Ready, set, go. Cell Cycle 2003;2:116-7.
36. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006;16:51-8.
37. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006;21:3-9.
38. Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004;22:3937-49.
39. Suzuki T, Nishiyama K, Yamamoto A, et al. Molecular cloning of a novel apoptosis-related gene, human Nap1 (NCKAP1), and its possible relation to Alzheimer disease. Genomics 2000;63:246-54.
40. Di Raimondo F, Palumbo GA, Romeo MA, et al. In vitro sensitivity of B-CLL cells to fludarabine and interferons. Leuk Lymphoma 1995;17:449-53.
41. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol 1999;26:107-14.
42. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 2001;14:13-20.
43. Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-cell survival. Blood 2005;106:2391-8.
44. Katzav S. Vav1: An oncogene that regulates specific transcriptional activation of T cells. Blood 2004;103:2443-51.
45. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-47.
46. Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-κB factors - the distant relatives. Int J Biochem Cell Biol 2004;36:1166-70.
47. Jelinek DF, Tschumper RC, Stolovitzky GA, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003;1:346-61.
48. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-52.
49. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with CLL. Blood 2005;106:3175-82.
50. Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549-57.
51. Zubiaur M, Izquierdo M, Terhorst C, Malavasi F, Sancho J. CD38 ligation results in activation of the Raf-1/mitogen-activated protein kinase and the CD3-ζ/ζ-associated protein-70 signaling pathways in Jurkat T lymphocytes. J Immunol 1997;159:193-205.
52. Mallone R, Funaro A, Zubiaur M, et al. Signaling through CD38 induces NK cell activation. Int Immunol 2001;13:397-409.